# Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)

> **NCT02605486** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 46 (actual)

## Conditions studied

- Metastatic Breast Cancer (MBC)

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Bicalutamide

## Key facts

- **NCT ID:** NCT02605486
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-11-11
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02605486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02605486, "Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02605486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*